Last reviewed · How we verify
Treatment of carcinoma in situ (CIS) of the urinary bladder — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Tice Bcg | bcg | Pfizer | Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC] | BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages. |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Treatment of carcinoma in situ (CIS) of the urinary bladder
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Treatment of carcinoma in situ (CIS) of the urinary bladder:
- Treatment of carcinoma in situ (CIS) of the urinary bladder treatment updates — RSS
- Treatment of carcinoma in situ (CIS) of the urinary bladder treatment updates — Atom
- Treatment of carcinoma in situ (CIS) of the urinary bladder treatment updates — JSON
Cite this brief
Drug Landscape (2026). Treatment of carcinoma in situ (CIS) of the urinary bladder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-of-carcinoma-in-situ-cis-of-the-urinary-bladder. Accessed 2026-06-10.
Related
- Treatment of carcinoma in situ (CIS) of the urinary bladder full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing